image credit- freepik
India's Sai Parenterals has announced that its Australian subsidiary, Noumed Pharmaceuticals, has successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading, multi-billion-dollar pharmacy chains with an expanded product portfolio, a longer agreement tenure, and a significantly higher agreement value - reflecting a trusted customer relationship.
The renewed agreement is valued at AUD 202 Million (approximately Rs 1300 crore) for the term - translating to about AUD 27 Million per annum - to be executed over an extended term of 7½ years — with a further 3-year extension option upon mutual consent. The agreement is also structured for continuous growth, as it targets the addition of 12 new products every year, steadily increasing the contract's value and scope every year over its life.
Effective 1st July 2026, the renewal cements Noumed's position as a preferred, trusted strategic supply partner to Australia's largest pharmacy networks, and materially strengthens Sai Parenterals' international business footprint.
This deal further cements Noumed's presence in the Australian OTC market, and expands Sai Parenterals' international pharmaceutical business.
